Investing in DNA

When it comes to investing, sometimes thinking small is best, says Forbes' Yuval Bar-Or. Progress in technology and innovative products associated with DNA sequencing and the human genome could mean investment opportunities. As the $1,000 (or cheaper) genome approaches, the implications are "at once wondrous and disturbing," says Bar-Or, who hold investments in Illumina and Life Technologies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.